Medical News

RSS

Study confirms efficacy and tolerability of lacosamide for uncontrolled POS

A recent multi-center study has confirmed earlier study results that 400 mg/day of lacosamide provides a good balance of efficacy and tolerability for patients with uncontrolled partial-onset seizures (POS), and doses of 600mg/day may provide additional benefit for some patients.

26 Feb 2010

RMEI, PIM jointly sponsor complimentary continuing education virtual lecture on HAE

Hereditary angioedema (HAE) can be difficult to accurately diagnose and equally difficult to effectively treat. To overcome the many obstacles to managing the care of patients with HAE, healthcare professionals must be aware of the most up-to-date clinical data regarding HAE diagnosis and treatment.

26 Feb 2010

Medicare fraud: Brookhaven Memorial Hospital Medical Center agrees to pay $2.92M for resolving allegations

Brookhaven Memorial Hospital Medical Center, a Long Island, N.Y.-based hospital, has agreed to pay $2.92 million, plus interest, to settle allegations that the hospital defrauded Medicare, the Justice Department announced today.

26 Feb 2010

House passes bill to repeal antitrust exemption for health insurers

he House passed legislation Wednesday (406-19) to strip health insurers of their federal antitrust exemption.

26 Feb 2010

Resverlogix commences enrollment in RVX-208 Phase 2 clinical trial for atherosclerosis in ACS patients

Resverlogix Corp. announced today that it has officially activated the first site for the ASSURE 1 trial and commenced enrollment of patients for dosing of RVX-208. ASSURE 1 is the second Resverlogix Phase 2 clinical trial, led by Cleveland Clinic. This trial will examine RVX-208, Resverlogix's oral small molecule therapy for the treatment of atherosclerosis, in patients with acute coronary syndrome (ACS). This preparatory acute coronary syndrome study will ensure that 50 percent of the enrolled patients receive the IVUS (intravascular ultrasound) assessment.

26 Feb 2010

Genta initiates new dose-ranging study of tesetaxel drug

Genta Incorporated announced that the Company has initiated a new dose-ranging study of tesetaxel, the Company’s novel oral tubulin inhibitor, using a weekly dosing regimen. Tesetaxel -- a late Phase 2 oncology product -- is the leading oral taxane currently in clinical development.

26 Feb 2010

USPTO issues notice of allowance for Vanda Pharmaceuticals' Fanapt long-acting injectable formulation

Vanda Pharmaceuticals Inc. announced today that the U.S. Patent and Trademark Office has issued a notice of allowance for its patent application of a microsphere, long-acting injectable formulation of its antipsychotic product, Fanapt™ (iloperidone). When issued, this U.S. patent will expire on October 30, 2022, and in addition, the U.S. Patent and Trademark Office has granted a patent term adjustment of 300 days, leading to an effective expiration date of August 26, 2023.

26 Feb 2010

Ferring Pharmaceuticals, GSN sign agreement to test Parental Support technology

Ferring Pharmaceuticals and Gene Security Network announced that they have signed an agreement to conduct a clinical trial of GSN's advanced preimplantation genetic diagnosis (PGD) technology, Parental Support™.

26 Feb 2010

Mathematics of sleep-wake cycle

Why can't I fall asleep? Will this new medication keep me up all night? Can I sleep off this cold? Despite decades of research, answers to these basic questions about one of our most essential bodily functions remain exceptionally difficult to answer. In fact, researchers still don't fully understand why we even sleep at all. In an effort to better understand the sleep-wake cycle and how it can go awry, researchers at Rensselaer Polytechnic Institute are taking a different approach than the traditional brain scans and sleep studies. They are using mathematics.

26 Feb 2010

Scientists identify new way to treat castrate resistant cells in prostate cancer patients

Monash University biomedical scientists have identified a new way to treat castrate resistant cells in prostate cancer sufferers - the most common cancer in Australian men.

25 Feb 2010

New fatigue rating scale predicts increased risk of heart attack in dialysis patients

For dialysis patients, high scores on a new fatigue rating scale predict an increased risk of heart attack or other cardiovascular events, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology.

25 Feb 2010

Connecticut has especially high insurance hikes, disability advocates worry about Medicaid cuts in Tennessee

The Hartford Courant: "With average rate hikes at 13 percent or more this year for most plans, Connecticut health insurance premiums appear to be rising faster than the nation's. A typical family plan in Connecticut sold through an employer costs about $14,500 -- an estimate based on the Kaiser Family Foundation's report on 2009 prices and this year's rates of growth.

25 Feb 2010

New research using MRI shows that childhood stress can lead to structural brain changes

New research using magnetic resonance imaging (MRI) shows that childhood stress such as abuse or emotional neglect, in particular when combined with genetic factors, can result in structural brain changes, rendering these people more vulnerable to developing depression. The study led by scientists at Trinity College Dublin has just been published in the international scientific journal, Neuropsychopharmacology.

25 Feb 2010

TMI's Glider balloon catheter for PTA of lesions in peripheral vasculature receives FDA marketing clearance

TriReme Medical, Inc. (TMI) announced today that it has received FDA clearance for its newest product, the Glider™ balloon catheter, for percutaneous transluminal angioplasty (PTA) of lesions in the peripheral vasculature including the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries.

25 Feb 2010

Bipartisanship unlikely after health summit; Party unity Obama's next best bet

Democratic and Republican lawmakers each have an opportunity to make bipartisan concessions during Thursday's summit - like warming to malpractice reform or publicly conceding Democratic plans would ultimately lower the deficit, respectively - but political pressure will likely push both sides towards their partisan ranks, Politico reports.

25 Feb 2010

BioMedix Vascular Solutions, Howard University Hospital to participate in Community Health Project and Demonstration

BioMedix Vascular Solutions, Inc. announced today that the company has partnered with Howard University Hospital, Department of Surgery to participate in a Community Health Project and Demonstration focused on diagnosing and treating the potentially life-threatening condition called Peripheral Arterial Disease (PAD).

25 Feb 2010

Poll: Health bills remain unpopular, but individual provisions get high marks

CNN: "Although the overall health care reform bills passed by the House of Representatives and the Senate are unpopular, many of the provisions in the existing bills are extremely popular, even among Republicans, according to a new national poll. A CNN/Opinion Research Corporation survey released Wednesday also indicates that only a quarter of the public want Congress to stop all work on health care, with nearly three quarters saying lawmakers should pass some kind of reform.

25 Feb 2010

APHA: Congressional leaders have to move forward on health reform focusing prevention and wellness

As President Obama and congressional leaders meet today for a health reform summit, the American Public Health Association urges them to move forward on comprehensive, affordable health reform with a focus on prevention and wellness.

25 Feb 2010

Amicus Therapeutics announces common stock "registered direct" offering

Amicus Therapeutics today announced that it has entered into definitive agreements dated February 25, 2010 with a select group of institutional investors to sell 4.95 million shares of its common stock and warrants to purchase 1.85 million shares of its common stock in a "registered direct" offering. The shares of common stock and warrants are being offered in units consisting of one share of common stock and one warrant to purchase 0.375 shares of common stock at a price of $3.74 per unit.

25 Feb 2010

Lawsuit alleges Medtronic illegally marketed stent device for unapproved use

A complaint filed in federal court last week "alleges Medtronic Inc. illegally marketed a relatively obscure medical device called a biliary stent in ways not approved by federal regulators," The (Minneapolis-St. Paul) Star Tribune reports.

25 Feb 2010

Medical News

Study confirms efficacy and tolerability of lacosamide for uncontrolled POS

RMEI, PIM jointly sponsor complimentary continuing education virtual lecture on HAE

Medicare fraud: Brookhaven Memorial Hospital Medical Center agrees to pay $2.92M for resolving allegations

House passes bill to repeal antitrust exemption for health insurers

Resverlogix commences enrollment in RVX-208 Phase 2 clinical trial for atherosclerosis in ACS patients

Genta initiates new dose-ranging study of tesetaxel drug

USPTO issues notice of allowance for Vanda Pharmaceuticals' Fanapt long-acting injectable formulation

Ferring Pharmaceuticals, GSN sign agreement to test Parental Support technology

Mathematics of sleep-wake cycle

Scientists identify new way to treat castrate resistant cells in prostate cancer patients

New fatigue rating scale predicts increased risk of heart attack in dialysis patients

Connecticut has especially high insurance hikes, disability advocates worry about Medicaid cuts in Tennessee

New research using MRI shows that childhood stress can lead to structural brain changes

TMI's Glider balloon catheter for PTA of lesions in peripheral vasculature receives FDA marketing clearance

Bipartisanship unlikely after health summit; Party unity Obama's next best bet

BioMedix Vascular Solutions, Howard University Hospital to participate in Community Health Project and Demonstration

Poll: Health bills remain unpopular, but individual provisions get high marks

APHA: Congressional leaders have to move forward on health reform focusing prevention and wellness

Amicus Therapeutics announces common stock "registered direct" offering

Lawsuit alleges Medtronic illegally marketed stent device for unapproved use

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Latest News